New hope for kids and adults with returning bone cancer?
NCT ID NCT07144254
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-phase trial tests a new drug called tegavivint combined with the chemotherapy gemcitabine in people whose osteosarcoma (a type of bone cancer) has returned or not responded to treatment. The main goal is to find the safest dose of the combination and see if it can control the cancer. About 24 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Arthur M. Blank Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.